New Delhi: The use of cell therapy to treat COVID-19 patients could reduce the risk of death from the disease by 60 per cent, according to a new study.
The systematic review and meta-analysis included 195 clinical trials of advanced cell therapies targeting COVID-19 conducted in 30 countries between January 2020 and December 2021, as well as 26 trials with results published by July 2022. to be done.
The findings of the study, conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States, were reported in the journal Frontiers in Immunology.
Cell therapy has advanced significantly in recent years and has been used to treat cancer and auto-immune, cardiovascular and infectious diseases. During the pandemic, it was used in several clinical trials to treat COVID-19.
Otavio Cabral-Marques said, “Our study is the first to review all the information on these experiences scattered around the world and verify through meta-analysis how cell therapy works when treating COVID-19 and related Complications are treated.” Professor in the Medical School of USP.
The technique uses stem cells and derivatives from the patient (autologous) or donor (allogeneic). The cells are cultured or modified in the laboratory before being administered.
According to the article, the most commonly used cell type in clinical trials related to the treatment of COVID-19 in this period were multipotent mesenchymal stem (stromal) cells from connective tissue.
According to the authors, despite the focus on cell therapy, emphasis should be placed on the real protection ensured by vaccination.
– IANS
The article is in Hindi
-